常规化疗联合替吉奥对乳腺肿瘤患者淋巴结转移的影响

Influence study of conventional chemotherapy plus Tegafur,Gimeracil and Oteracil Potassium Capsules in the lymphatic metastasis for breast neoplasm patients

目的:研究常规化疗联合替吉奥对乳腺肿瘤患者淋巴结转移的影响。方法:临床纳入2016年5月至2017年5月期间我院收治的84例乳腺肿瘤患者进行研究,按随机数字表法分为两组各42例。其中42例患者采用常规化疗治疗作为对照组;另42例患者在常规化疗的基础上给予替吉奥治疗作为观察组。观察患者淋巴转移、肿瘤标志物水平和不良反应情况。结果:观察组淋巴结转移率为7.14%,明显低于对照组的28.57%,P<0.05。治疗前两组患者CEA、CA15-3以及CA125水平对比无差异,P>0.05;治疗后观察组CEA、CA15-3以及CA125水平明显低于对照组,P<0.05。观察组不良反应发生率为21.43%,对照组为16.67%,两组不良反应发生率对比无差异,P>0.05。结论:替吉奥可有效抑制乳腺肿瘤的淋巴结转移,促进化疗效果,且安全性较高,值得临床应用及推广。

Objective:To study the influence of conventional chemotherapy plus Tegafur,Gimeracil and Oteracil Potassium Capsules on the lymphatic metastasis for breast neoplasm patients.Methods:84 breast neoplasm patients,between May 2016 and May 2017,admitted to our hospital were enrolled into the study.Random number table was used for 42 cases in each group.The control group was treated with conventional chemotherapy.The observation group received with Tegafur,Gimeracil and Oteracil Potassium Capsules regimen.The lymphatic metastasis rate,tumor markers and adverse reactions were evaluated.Results:The lymphatic metastasis rate in the observation group(7.14%) was significantly lower than that in control group(28.57%)(P<0.05).Before treatment,the values of CEA(carcino-embryonic antigen),CA15-3(carbohydrate antigen 15-3) and CA125(cancer antigen 125) for two groups were not significantly different(P>0.05).After treatment,the values of CEA,CA15-3 and CA125 in the observation group were significantly lower than control group(P<0.05).The adverse event rate in the observation group(21.43%) and control group(16.67%) was not significantly different(P>0.05).Conclusion:The Tegafur,Gimeracil and Oteracil Potassium Capsules can efficiently inhibit the lymphatic metastasis,and increase the chemotherapy efficacy and clinical safety,which is worthy of clinical application and promotion.